Thrombocytopenia Market Insights, Epidemiology and Market Forecast, 2027 – ResearchAndMarkets.com

The “Thrombocytopenia
– Market Insights, Epidemiology and Market Forecast-2027” drug
pipelines has been added to ResearchAndMarkets.com’s

The market of Thrombocytopenia in 7MM was found to be USD 1,248 million
in 2016.

Thrombocytopenia – Market Insights, Epidemiology and Market
Forecast-2027′ report delivers an in-depth understanding of the disease,
historical & forecasted epidemiology as well as the market trends of
Thrombocytopenia in the United States, EU5 (Germany, Spain, Italy,
France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs
having the potential to get launched in the forecast period, market
share of the individual therapies, current and forecasted market size of
Thrombocytopenia from 2016 to 2027 segmented by seven major markets. The
Report also covers current treatment practice/algorithm, market drivers,
market barriers and unmet medical needs to curate best of the
opportunities and assess underlying potential of the market.

Key Topics Covered:

1. Key Insights

2. Thrombocytopenia Market Overview at a Glance

2.1. Market Share (%) Distribution of Thrombocytopenia in 2017

2.2. Market Share (%) Distribution of Thrombocytopenia in 2027

3. Disease Background and Overview: Thrombocytopenia

3.1. Introduction

3.2. Causes of Thrombocytopenia

3.3. Pathogenesis

3.4. Pathophysiology

3.5. Etiology

3.6. Symptoms

3.7. Diagnosis and Treatment

3.8. The American Society of Hematology 2011 evidence-based practice
guideline for immune thrombocytopenia

3.9. Management of thrombocytopenia

3.10. First Line Therapies

3.11. Second and Third Line Therapies

3.12. Diagnostic and treatment guidelines form thrombotic
thrombocytopenic purpura (TTP) 2017 in Japan

3.13. Treatment of Heparin-induced Thrombocytopenia (HIT)

4. Epidemiology and Patient Population

4.1. Key Findings

4.2. Population and Forecast Parameters

4.3. 7MM Prevalent Population of Thrombocytopenia

4.4. Country Wise-Epidemiology of Thrombocytopenia

5. Unmet needs

6. Marketed Products

7. Octagam: Octapharma USA

7.1. Product Description

7.2. Regulatory Milestones

7.3. Advantages & Disadvantages

7.4. Safety and Efficacy of Octagam

7.5. Side effects of Octagam

7.6. Product Profile

8. Nplate(AMG-531): Amgen

8.1. Product Description

8.2. Regulatory Milestones

8.3. Advantages & Disadvantages

8.4. Safety and Efficacy of Nplate

8.5. Side effects of Nplate

8.6. Product Profile

9. MULPLETA (Lusutrombopag): Shionogi

9.1. Product Description

9.2. Regulatory Milestones

9.3. Safety and Efficacy of Lusutrombopag/MULPLETA

9.4. Side effects of MULPLETA

9.5. Product Profile

10. Privigen: CSL Behring

11. Rhophylac: CSL Behring

12. Emerging Therapies

13. Filed & Phase III Drugs

13.1. Avatrombopag: Dova Pharmaceuticals

13.2. Fostamatinib: Rigel Pharmaceuticals

13.3. Caplacizumab: Ablynx

13.4. BT-595: Biotest

13.5. SHP655: Shire

14. Phase II Drugs

14.1. PRN-1008: Principia Biopharma

14.2. PRTX-100: Protalex

14.3. Rozanolixizumab: UCB Biopharma

14.4. Efgartigimod: Argenx

14.5. Veltuzumab: Immunomedics

15. Thrombocytopenia: Market Analysis

15.1. Key Findings

16. Thrombocytopenia: Total Market Size in 7MM

16.1. Total Market Size of Thrombocytopenia in 7MM

16.2. Type Specific Market Size of Thrombocytopenia in 7MM

17. Market Size of Thrombocytopenia by Country

18. Market Drivers

19. Market Barriers

20. Appendix

Companies Mentioned

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/gl9vmc/thrombocytopenia?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20180615005821/en/